ClinicalTrials.gg
Not yet recruitingNCT07556120Updated Aug 12, 2026

Efficacy and Safety of HN2301 in Patients With Generalized Myasthenia Gravis (MG)

A Phase 1 interventional study of HN2301 injection in Generalized Myasthenia Gravis, sponsored by Shenzhen MagicRNA Biotechnology Co., Ltd. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-08-12.

Sponsored by Shenzhen MagicRNA Biotechnology Co., Ltd · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 88 studies in Myasthenia Gravis with a site in China — 48 open to participants now, 60 under way, 17 of them phase 3. Myasthenia Gravis · China.

Planned enrollment
61st of 67
6 · median 40
Started
2026
with 17 others
Phase 1
25 of 88
20 open now
Primary completion
2027-05
later than 30 of 59 live
Registered
81st of 88
by date

Among the 88 studies in Myasthenia Gravis with a site in China, this one is the 61st largest by planned enrollment of the 67 interventional ones that give a count, is one of 18 that started in 2026, is one of 25 in phase 1, reaches primary completion later than 30 of the 59 other live ones, and was the 81st registered.

Myasthenia Gravis

331 studies on the registry are indexed under Myasthenia Gravis; 145 are open to participants now.

Browse Myasthenia Gravis studies →

Open to participants now

48 of the 88 studies in Myasthenia Gravis with a site in China are open now. Recruiting first, the newest first:

43 more — sign in →

All 48 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 104 Myasthenia Gravis studies recruiting now, 64 (62%) set no upper age limit and 23 (22%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 88 studies in Myasthenia Gravis with a site in China, or all of them as a file.
02

Study summary

This is an open label, single arm study, to evaluate safety, tolerability and preliminary efficacy of HN2301 in patients with Generalized Myasthenia Gravis.

Read the detailed description

This study consists of a screening period of up to 4 weeks, a treatment period, and a follow-up period of 1 year.

03

Conditions studied

  • Generalized Myasthenia Gravis

Browse trials for

Keywords

  • MG
  • in vivo CART
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age: 18-80 years, no gender restriction;
  • Confirmed diagnosis of generalized myasthenia gravis (MG) with positive AchR or MuSK antibodies, meeting at least one of the following conditions#(1) Repetitive nerve stimulation suggesting neuromuscular transmission defect; (2) Positive response to neostigmine test; (3) Clinically judged improvement of --MG symptoms after oral cholinesterase inhibitor therapy;
  • Clinical classification of MG according to MGFA types IIa-IVb (including IIa, IIb, IIIa, IIIb, IVa, IVb);
  • Baseline MG-ADL score ≥6, ocular-related score \<50%;
  • Poor response and/or lack of efficacy under standard therapies;
  • Minimum > 12 weeks;
  • Adequate bone marrow, coagulation, cardiopulmonary, liver, and renal function.

Exclusion criteria

Exclusion Criteria:

  • Subjects positive for surface antigen (HBsAg) and/or hepatitis B core antibody (HBcAb) with detectable or quantifiable HBV DNA, positive for antibody (HCV Ab) with detectable or quantifiable HCV RNA, positive for antibody, positive CMV DNA, or CMV DNA above the lower limit of detection; positive for syphilis antigen or antibody;
  • Presence of other uncontrolled active infections;
  • History of major organ transplantation (e.g., heart, lung, liver, kidney) or bone marrow/hematopoietic stem cell transplantation;
  • Pregnant or breastfeeding women;
  • Receipt of any mRNA-LNP products or other LNP-based drugs within the past two years;
  • History of any of the following cardiovascular conditions within 6 months prior to screening: (NYHA) Class III or IV heart failure, myocardial infarction, unstable angina, uncontrolled or symptomatic atrial arrhythmias, any ventricular arrhythmias, or other cardiac disease;
  • History of ≥Grade 2 bleeding events within 30 days prior to screening, or requiring long-term continuous anticoagulation therapy (e.g., warfarin, low molecular weight heparin, Xa factor inhibitors);
  • History of within 30 days prior to screening;
  • Severe central nervous system diseases or pathological changes, including but not limited to: cerebrovascular accident, aneurysm, epilepsy, seizures/convulsions, aphasia, stroke, severe brain injury, dementia, Parkinson's disease, cerebellar disorders, organic brain syndromes, or psychosis;
  • History of asthma or severe allergies;
  • Patients combined with other malignant tumors;
  • Any condition that, in the investigator's opinion, may increase the patient's risk or interfere with study assessments.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (estimated)

Study arms

  • Experimental
    HN2301 treatment group

    Participants will receive HN2301 Injection at the specified dose level and on the specified study days.

    Drug: HN2301 injection

Interventions

  • Dosing will begin at a lower dose level and may be escalated to dose levels considered safe and potentially effective according to the study protocol.

    Also known as: in vivo CAR-T

06

What researchers measure

Primary outcomes

  1. Incidence of treatment-emergent adverse events (TEAEs)

    Incidence, nature, and severity of treatment-emergent adverse events, assessed according to the study protocol and applicable toxicity grading criteria.

    Time frame: Up to 3 months

Secondary outcomes

  1. in vivo CAR T cell production

    Assessment of in vivo CAR-T cell production, defined by the proportion of CAR-expressing T cells in peripheral blood as measured by flow cytometry.

    Time frame: Up to14 days

  2. Absolute B-cell count in peripheral blood

    Assessment of peripheral blood absolute B-cell count (cells/μL), including naive B cells and memory B cells, by flow cytometry.

    Time frame: Up to 12 months

  3. Changes from baseline in Myasthenia Gravis Activities of Daily Living(MG-ADL) score

    Proportion of patients ≥2 points. A total score can fall between 0 and 24, with a higher score representing a more significant degree of disease activity.

    Time frame: Up to 12 months]

  4. Changes from baseline in Myasthenia Gravis Composite (MGC) score

    Proportion of patients ≥3-point reduction.The total score is 50 points. The higher the score, the more severe the condition is indicated.

    Time frame: Up to 12 months

  5. Changes from baseline in Quantitative Myasthenia Gravis (QMG) score

    Proportion of patients ≥3-point reduction. To assess the muscle strength and endurance of the affected muscles in patients with myasthenia gravis, thereby reflecting the severity of the disease,including 8 items, each scored on a scale of 0 to 3, with 3 indicating the most severe degree.

    Time frame: Up to 12 months]

  6. Changes from baseline in revised Myasthenia Gravis Quality of Life-15 score (MG-QOL15r)

    To assess important aspects of the patient's experience related to MG, scores each of 15 items 0-2 (max score 30).The higher the score, the worse the patient's quality of life.

    Time frame: Up to 12 months

  7. Changes in acetylcholine receptor (AchR) antibody levels after treatment

    Differences in AchR antibody post-administration vs. baseline

    Time frame: Up to 12 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2026; primary completion for May 2027, 5 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 16, 2026
First posted
Apr 29, 2026
StartEst.
Dec 31, 2026
Primary completionEst.
May 31, 2027
CompletionEst.
Dec 31, 2028
Last update
Aug 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07556120
Lead sponsor
Shenzhen MagicRNA Biotechnology Co., Ltd
Collaborators
The First Affiliated Hospital of University of Science and Technology of China
Responsible party
Sponsor
First posted
Apr 29, 2026
Start date
Dec 31, 2026 (estimated)
Primary completion
May 31, 2027 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Aug 12, 2026

Study contacts

Wen Xu
Contact
Xuwen6779@ustc.edu.cn
+86055162284920
Zexiu Xiao
Contact
xiaozexiu@magicrna.com
+86075527109036
Wen Xu
principal investigator · The First Affiliated Hospital of University of Science and Technology of China
Yan Jiang
principal investigator · The First Affiliated Hospital of University of Science and Technology of China

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HN2301

Start the discussion